Activists file post grant opposition to challenge a patent prevents purchase of cheaper treatment for hepatitis C
In GTPI’s opinion, this concession is undeserved. The main argument is that the patent
lacks sufficiency disclosure, ie, it does not have the level of detail necessary for the
technology described therein to be reproduced by a person skilled in the art. This is
fundamental to justify the granting of the patent.
Benefits of landmark HIV drug outweigh risks of birth defects, study shows
The antiretroviral drug dolutegravir, taken in conjunction with other drugs to suppress an HIV patient’s viral load and to stop them passing the virus to others, is considered one of the best HIV drugs available and has become the cornerstone of treatment in many richer countries since it was first introduced in the United States in 2013.Read more